血液肿瘤的诊治ppt课件.pptVIP

Purpose of the study Based on the retrospective study of large series in a representative centre, conclude clinical features, response to current treatment and prognosis of multiple myeloma in China; To make new strategy of diagnosis and treatment of multiple myelom according to the advance of basic and clinical research on multiple myeloma, Patients 606 MM patients were recorded in BHD, CAMS from 1980 to 2002. These patients came from 26 provinces. 432 were evaluated for clinical features. 257 were evaluated for survival analysis with enough follow up data. 195 were treated with conventional therapy over 6 months and evaluated for Tx results. Treatment for MM in BDH 1980s-1996: conventional CT with MP, M2, COP, VECP. 1997: VAD, HDT+ASCT, Allo-BMT 2000s: Thalidomide ±MP, VAD/HD-Dexm ± Thalidomide 2005: Bortezomib + HD-Dexm Epidemiology Annual incidence: USA: White 4/100,000 Black 10/100,000 Europe: 2.5-3.5/100,000 Asia: 1.0/100,000 China: no definitive data, probably 1.0/100,000 Age at diagnosis: Western: peak age 65-70 y, median age 68y China: peak age 55-65 y, median age 55y Male to female ratio: 2.5:1 Age and gender distribution of 432 patients with MM at diagnosis Statistics data of Blood Disease Hospital, CAMS 2004, n=432 Male : female＝2.35：1 peak：55～65y，median：57y Comparison of age at diagnosis BDH ( %) Mayo Clin(%) n＝432 n=1027 40 10.2 2.0 40－49 18.8 8.0 50－59 32.9 20.0 60－69 26.8 32.0 70 11.3 38.0 monoclonal-protein type in 312 patients A retrospective study of 23 years in BDH,CAMS,2004 A retrospective study of 23 year